ATB Therapeutics Secures €54 Million in Series A Financing Led by EQT Life Sciences
Deal News | Nov 18, 2024 | EQT
EQT Life Sciences has announced that its LSP 7 fund led a €54 million Series A financing round for ATB Therapeutics. This round will accelerate the clinical development of ATB's novel therapeutic antibodies derived from its proprietary ATBioFarm platform. The financing was co-led with MRL Ventures Fund, the venture arm of Merck & Co, and included contributions from V-Bio, VIVES Partners, and several Belgian entities. ATB Therapeutics, based in Belgium, focuses on developing biologics with innovative cell-killing mechanisms. The company plans to use the funds to further develop its pipeline and expand its production facilities in Ghent and Marche-en-Famenne. The article also notes the appointment of renowned industry veteran Mark Throsby as ATB's Executive Chairman, bringing expertise that complements their developments. The involvement of seasoned biotech investors on ATB's board underscores the confidence in ATB's vision. The expansion will support ATB's mission to deliver new therapies for oncology and immunology needs.
Sectors
- Biotechnology
- Venture Capital
Geography
- Belgium – ATB Therapeutics is based in Marche-en-Famenne, Belgium, and has expansion plans in Ghent.
- United States – MRL Ventures Fund, a significant co-leader of the funding round, is the venture arm of Merck & Co., Inc., based in Rahway, New Jersey.
Industry
- Biotechnology – The article focuses on ATB Therapeutics, a company dedicated to innovative antibody therapy development, which is a key segment of the biotechnology industry.
- Venture Capital – The financing round led by EQT Life Sciences and contributions from other venture entities underscores the venture capital activities in the life sciences sector.
Financials
- €54 Million – The total amount raised in the Series A financing round led by EQT Life Sciences for ATB Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ATB Therapeutics | Target Company | Company | A biotechnology company focusing on innovative antibody therapies, based in Belgium. |
| EQT Life Sciences | Lead Investor | Company | A division of EQT, formed to focus on life sciences and healthcare investments. |
| MRL Ventures Fund | Co-Lead Investor | Company | The corporate venture arm of Merck & Co., Inc. |
| Mark Throsby | Executive Chairman | Person | Industry veteran and former CSO of Merus, joining ATB Therapeutics. |
| Bertrand Magy | CEO and Co-founder | Person | CEO and co-founder of ATB Therapeutics. |
| John de Koning | Board Member | Person | Partner at EQT and a board member of ATB Therapeutics. |
| Karin Kleinhans | Board Member | Person | Partner at MRL Ventures Fund and a board member of ATB Therapeutics. |
| V-Bio | Investor | Company | A venture capital firm contributing to the Series A funding. |
| VIVES Partners | Investor | Company | Venture capital firm involved in the funding round. |
| SFPIM | Investor | Company | Belgian sovereign fund supporting the investment round. |
| Wallonie Entreprendre | Investor | Company | Belgian regional investment authority contributing to the funding. |
| Sambrinvest | Investor | Company | Belgian investor supporting the Series A funding. |